[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ldrt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ldrt":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627841","phase-1-ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer-100627841",false,"NCT07453875","LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","A Prospective, Single-center, Single-arm Clinical Study on the Safety and Efficacy of LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","TRIUNITE06","Inclusion Criteria:\n\n1. Age between18 and 75 years old.\n2. Histologically confirmed gastric cancer\u002Fcolon cancer, and diagnosed as peritoneal metastasis of tumor through laparoscopy\u002Fpuncture (patients must have metastatic tumors located within the peritoneal cavity).\n3. An Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n4. According to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, patients must have measurable disease within the irradiated area.\n5. Expected survival period≥3 months\n6. Adequate cardiac function (Left Ventricular Ejection Fractions \\> 50%), hepatic function (total serum bilirubin ≤ 1.5 ×upper limit of normal, alanine aminotransferase or aspartate aminotransferase ≤ 2.5 × upper limit of normal), renal function (serum creatinine ≤ 1.5 × ULN or glomerular filtration rate \\> 60 ml\u002Fmin, based on Cockcroft-Gault), and hematopoietic function (white blood cells ≥ 4.0 × 109 cells per L, neutrophils ≥ 1.5 × 109 cells per L, hemoglobin ≥ 90 g\u002FL, platelets ≥ 100 × 109 cells per L).\n7. Sign the informed consent and have good compliance.\n\nExclusion Criteria:\n\n1. Presence of distant metastasis other than peritoneal metastasis (ovarian metastasis is allowed);\n2. Presence of uncontrolled clinical symptoms or diseases of the heart, including but not limited to: (1) NYHA class II or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias that have not been clinically intervened or remain uncontrolled after clinical intervention;\n3. Upper gastrointestinal obstruction or physiological dysfunction, or suffering from malabsorption syndrome, which may affect the absorption of oral drugs;\n4. Severe infection (CTCAE \\> grade 2) or other concomitant diseases within 4 weeks before the first use of the study drug, such as severe pneumonia, bacteremia, or infectious complications requiring hospitalization; baseline chest imaging shows active pulmonary inflammation, or symptoms and signs of infection within 14 days before the first use of the study drug, or requiring oral or intravenous antibiotic treatment, except for prophylactic use of antibiotics; active pulmonary tuberculosis infection is found through medical history or CT examination, or there is a history of active pulmonary tuberculosis within 1 year before enrollment, or there is a history of active pulmonary tuberculosis more than 1 year ago but without regular treatment;\n5. History of immunodeficiency (including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation or allogeneic bone marrow transplantation);\n6. Moderate or severe renal impairment (creatinine clearance ≤ 50 ml\u002Fmin);\n7. Allergy to paclitaxel, oxaliplatin, monoclonal antibodies or any component of the study drug;\n8. Pregnant or lactating women;\n9. Presence of clinically detectable second primary malignancy, or a history of other malignancies within 5 years, excluding adequately treated non-melanoma skin cancer, cervical carcinoma in situ, and superficial bladder tumors (non-invasive tumors, or carcinoma in situ, or T1);\n10. Uncontrolled epilepsy, central nervous system disease or mental disorder, as judged by the investigator to be clinically significant enough to prevent signing the informed consent or affect the patient's compliance with drug treatment.","ALL","18 Years","75 Years",{"count":21,"type":22},9,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","There have been initial explorations on the treatment of peritoneal metastasis of gastric and colorectal cancer both at home and abroad. However, the comprehensive treatment plan of \"LDRT + NIPEC + immunotherapy + systemic therapy\" has not been reported either domestically or internationally. This study will explore the safety and efficacy of total abdominal low-dose radiotherapy followed by NIPEC and PD-1 treatment for peritoneal metastasis of gastric and colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.",[28,29],"Peritoneal Metastasis of Gastric and Colorectal Cancer","LDRT",[31,29,32,33],"Gastric and colorectal cancer","NIPS","Immunochemotherapy","NOT_YET_RECRUITING","2026-04-22",{"date":37,"type":38},"2026-04-27","ACTUAL",{"date":40,"type":22},"2026-05",{"date":42,"type":22},"2027-12-30",{"name":44,"class":45},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100581296","phase-1-ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis-100581296","NCT06848465","LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis","A Phase Ib Trial on the Safety and Feasibility of Low Dose Radiotherapy (LDRT) Combined With Immunochemotherapy for Colorectal Cancer With Liver-limited Metastasis","Inclusion Criteria:\n\n1. Age between18 and 75 years old.\n2. Histopathological confirmed MSS\u002FpMMR adenocarcinoma of the colon or rectum.\n3. The clinical baseline stage of rectal cancer assessed by MRI\u002FCT\u002FTransrectal ultrasound was T3-4Nx or TXN1-2.\n4. Simultaneous liver metastasis confirmed by imaging examination.\n5. No previous antitumor treatment.\n6. An Eastern Cooperative Oncology Group (ECOG) performance status ≤1.\n7. Adequate cardiac function (Left Ventricular Ejection Fractions \\> 50%), hepatic function (total serum bilirubin ≤ 1.5 × upper limit of normal, alanine aminotransferase or aspartate aminotransferase ≤ 2.5 × upper limit of normal), renal function (serum creatinine ≤ 1.5 × ULN or glomerular filtration rate \\> 60 ml\u002Fmin, based on Cockcroft-Gault), and hematopoietic function (white blood cells ≥ 4.0 × 109 cells per L, neutrophils ≥ 1.5 × 109 cells per L, hemoglobin ≥ 90 g\u002FL, platelets ≥ 100 × 109 cells per L).\n8. Sign the informed consent and have good compliance.\n\nExclusion Criteria:\n\n1. Distant metastasis from other than the liver.\n2. BMI \\\u003C 18.5 kg\u002Fm² or weight loss ≥ 10% within the past 6 months (with consideration of the impact of large amounts of pleural and ascitic fluid on body weight).\n3. Received any of the following treatments: any investigational drug; enrolled in another clinical trial concurrently, unless it is an observational (non-interventional) clinical study; received anti-tumor vaccines or live vaccines.\n4. Active autoimmune diseases, or a history of autoimmune diseases. A history of liver disease including, but not limited to HBV infection or HBV DNA positive(≥1×10\\^4\u002Fml), HCV infection or HCV DNA positive(≥1×10\\^3\u002Fml) and liver cirrhosis.\n5. History of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation.\n6. A history of heart disease within 6 months (including congestive heart failure, acute myocardial infarction, severe\u002Funstable angina, coronary artery bypass grafting, cardiac insufficiency ≥ NYHA grade 2 and LVEF\\\u003C50%).\n7. The presence of a clinically detectable second primary malignancy, or history of other malignancies within 5 years excluding adequately treated non-melanoma skin cancer, carcinoma in situ of cervix and superficial bladder tumour (non-invasive tumour, or carcinoma in situ, or T1).\n8. Pregnant or lactating women.\n9. The investigator considers that the subject is not suitable to participate in this clinical study due to any clinical or laboratory abnormalities or compliance problems.","80 Years",{"count":21,"type":22},[25],"In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy. More over, LDRT may enhance the antitumor effect of immunotherapy by altering the tumor immune microenvironment (TIME) and adjusting the immune response. In this study, we will explore the safety and feasibility of LDRT and immunochemotherapy in liver metastatic colorectal cancer. 9-18 participants will be enrolled in this study. All will take part at Daping Hospital, Army Medical University.",[59,60,29],"Colorectal Cancer","Liver Metastasis","RECRUITING","2026-04-02",{"date":64,"type":38},"2026-04-03",{"date":66,"type":38},"2025-02-28",{"date":68,"type":22},"2027-11-30",{"name":44,"class":45},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100616961","phase-1-ldrt-combined-with-pucotenlimab-and-standard-therapy-for-advanced-pancreatic-cancer-a-single-arm-study-100616961","NCT07312422","LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","An Open-label, Single-center, Single-arm Study to Evaluate the Efficacy and Safety of Low-dose Radiation Therapy Combined With Pultelimab and Standard Treatment in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of gender;\n* ECOG score of 0 to 1;\n* Patients with histologically or cytologically confirmed pancreatic malignancy;\n* No prior treatment with PD-1 or PD-L1 inhibitors;\n* Presence of a radiotherapeutically eligible target lesion (excluding bone metastases);\n* Subjects voluntarily participate in the study and provide signed informed consent.\n\nExclusion Criteria:\n\n* Previous history of radiotherapy;\n* Uncontrolled chronic infectious or non-infectious diseases, including but not limited to: medication-refractory heart failure, poorly controlled hypertension, etc.;\n* Active or clinically uncontrolled severe infections;\n* History of psychoactive drug abuse that cannot be abstained from, or patients with psychiatric disorders;\n* Pregnant or lactating women, or patients of childbearing potential who are unwilling or unable to adopt effective contraceptive measures;\n* Other conditions deemed by the investigator as potentially affecting the conduct of the clinical study or the interpretation of study results.",{"count":78,"type":22},10,[25,80],"PHASE2","To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.",[83,84,85,29,86],"Pancreatic Cancer","PD-L1","PD-1 Inhibitor","Proterizumab",[88,89,29,90],"pancreatic cancer","PD-1 inhibitor","immunotherapy","2026-01-22",{"date":93,"type":38},"2026-01-26",{"date":95,"type":38},"2025-09-30",{"date":97,"type":22},"2026-10-30",{"name":99,"class":45},"Zhejiang Provincial People's Hospital",1]